A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Finding the big spenders beyond big pharma
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
Big pharma holds steady on research spending
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.